Integra Lifesciences Holdings layoffs, on the record
Every job cut, severance charge and restructuring Integra Lifesciences Holdings reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from 3,946 to 4,427.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | 3,946 | As of December 31, 2023 |
| 10-K for 2024 | approximately 4,396 | December 31, 2024 |
| 10-K for 2025 | 4,427 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryUndertook cost-saving initiatives in 2023 to consolidate manufacturing and distribution, eliminate duplicative positions, and realign sales and marketing activities.
Word for word“In support of our continued focus on product margins we closed a manufacturing facility located in France in 2022, and transferred production to our existing Switzerland facility.” 10-K for 2023
Our summaryIncurred employee termination costs on sales force restructuring activities, recorded in 2023 operating results.
Word for word“The Company incurred employee termination costs on sales force restructuring activities in the consolidated statement of operations for the year ended December 31, 2023.” 10-K for 2023
Our summaryIncurred employee termination costs on restructuring tied to closure of a manufacturing facility in France and other reorganization projects.
Word for word“In addition, the Company incurred employee termination costs on restructuring activities associated with a closure of a manufacturing facility in France and other reorganization projects in the consolidated statement of operations for the year ended December 31, 2022.” 10-K for 2023
Our summaryReported structural optimization special charges, which relate to restructuring and consolidation activities.
Word for word“Structural optimization charges 23,020 23,072 Boston recall expenses (2) 40,034 EU medical device regulation 46,559 45,147 Total 134,786 49,370 (1) See Note 4, Acquisitions and Divestitures of the Notes to Consolidated Financial Statements (Part IV, Item 15 of this Annual Report on Form 10-K) for details.” 10-K for 2023
Our summaryThe company undertook cost-saving initiatives to consolidate manufacturing and distribution, eliminate duplicative positions, and realign sales and marketing activities.
Word for word“As a result of our ongoing acquisition strategy and significant growth in recent years, we have undertaken cost-saving initiatives to consolidate manufacturing operations, distribution facilities and transfer activities, eliminate duplicative positions, realign various sales and marketing activities, and expand and upgrade production capacity for our regenerative technology products.” 10-K for 2024
Our summaryThe company recorded employee termination costs on restructuring activities in its 2024 statement of operations.
Word for word“The Company incurred employee termination costs on restructuring activities of $5.2 million in the consolidated statement of operations for the year ended December 31, 2024.” 10-K for 2024
Our summaryThe company's restructuring accrual for employee termination costs rose from the prior year, with 2024 charges of about $4.9 million across cost lines and payments of about $1.9 million.
Word for word“The following table summarizes the restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the years ended December 31, 2024 and 2023.” 10-K for 2024
Our summaryThe company approved a restructuring initiative in the fourth quarter of 2025 to strengthen its supply chain and improve operational performance, and expects about $12.6 million in severance and other employee costs.
Word for word“We expect to incur aggregate restructuring costs associated with this initiative of approximately $12.6 million related to severance and other employee costs.” 10-K for 2025
Our summaryThe company recorded $8.5 million of restructuring costs for this initiative in 2025.
Word for word“We incurred $8.5 million of restructuring related costs related to this initiative during the year ended December 31, 2025.” 10-K for 2025
Our summaryThe company ran cost-saving initiatives in 2024 and 2025 that consolidated manufacturing and distribution, eliminated duplicate positions, and realigned sales and marketing.
Word for word“As a result of our ongoing acquisition strategy and significant growth in recent years, we have undertaken cost-saving initiatives in 2024 and 2025 to consolidate manufacturing operations, distribution facilities and transfer activities, eliminate duplicative positions, realign various sales and marketing activities, and expand and upgrade production capacity for our regenerative technology products.” 10-K for 2025
Our summaryThe compensation committee adopted an Executive Severance Plan that gives severance benefits to the executive leadership team upon a qualifying termination.
Word for word“On February 24, 2026, the Compensation Committee of the Board of Directors of Integra LifeSciences Holdings Corporation (the “Company”) adopted the Integra LifeSciences Executive Separation Pay Plan (the “Executive Severance Plan”).” 10-K for 2025
Integra Lifesciences Holdings has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Integra Lifesciences Holdings’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.